Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 120
Filtrar
1.
Clin Exp Immunol ; 123(3): 428-34, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11298130

RESUMEN

The purpose of the present study was to elucidate the role of oestrogen in the pathogenesis of Mycobacterium avium complex (MAC) pulmonary disease, which occurs most frequently in postmenopausal women. The study was carried out in a murine infectious model using ovariectomized DBA/2 female mice. Infection with MAC was established by intratracheal administration of bacilli. In some experiments, ovariectomized mice were treated with exogenous 17 beta-estradiol (E2). The number of bacilli in the lungs of infected mice which received ovariectomy was significantly larger than that in the lungs of sham-operated control mice, and treatment of ovariectomized mice with exogenous E2 restored the burden of bacilli to the same level as that in the sham-operated control mice. We next examined the effect of E2 in vitro using bone marrow-derived macrophages obtained from DBA/2 female mice. The macrophages showed bacteriostatic activity against MAC after treatment with interferon-gamma (IFN-gamma) and this activity was further enhanced by the exogenous addition of E2 to the culture medium. In parallel with these findings, E2 augmented the production of reactive nitrogen intermediates (RNI) by macrophages pretreated with IFN-gamma and stimulated with MAC, as shown by evaluating nitrite production and inducible nitric oxide synthase mRNA expression. These findings taken together suggest that absence of endogenous oestrogen appears to be responsible for the development of MAC pulmonary disease in this mouse model and that the enhancement by E2 of anti-MAC activity of murine macrophages induced through increased RNI production may play some role in resistance to MAC infection.


Asunto(s)
Estradiol/metabolismo , Complejo Mycobacterium avium/efectos de los fármacos , Infección por Mycobacterium avium-intracellulare/etiología , Tuberculosis Pulmonar/etiología , Animales , Células de la Médula Ósea/microbiología , Femenino , Inmunidad Innata , Macrófagos/microbiología , Ratones , Ratones Endogámicos DBA , Óxido Nítrico Sintasa/biosíntesis , Óxido Nítrico Sintasa de Tipo II , Ovariectomía
2.
Am J Respir Crit Care Med ; 160(3): 866-72, 1999 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10471610

RESUMEN

We have investigated the efficacy of a clarithromycin-containing four-drug regimen for Mycobacterium avium complex (MAC) pulmonary disease in 46 patients without acquired immunodeficiency syndrome (AIDS). The patients were 14 males and 32 females with a mean age of 60.9 +/- 11.5 yr. Patients received 10 mg/kg/d of clarithromycin plus ethambutol, rifampin, and initial kanamycin and subsequent quinolone for 24 mo. Seven patients (15.2%) were dropped in the first 6 mo. Among 39 patients who received more than 6 mo of therapy, 28 patients (71.8%) converted their sputa to negative: 26 of 31 patients (83.9%) infected with clarithromycin-susceptible strains and two of eight patients (25.0%) with resistant or intermediate strains. The timing of sputum conversion was 3.6 +/- 1.9 mo, with a range of 2 to 9 mo. The conversion rate was significantly lower in patients who were infected with clarithromycin-resistant or intermediate strains, who had had prior therapy (55.0% versus 89.5%), or who were acid-fast bacilli (AFB) smear-positive at entry (60.7% versus 100%). The age and sex of patients, the species of pathogen (M. avium or M. intracellulare), type and extent of the disease, and the use of kanamycin did not significantly affect the conversion rate. Although the regimen was efficacious for newly treated patients, frequent adverse reactions and a low conversion rate of sputum in retreated patients are problems that remain to be solved.


Asunto(s)
Antibacterianos/uso terapéutico , Claritromicina/uso terapéutico , Infección por Mycobacterium avium-intracellulare/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antiinfecciosos/uso terapéutico , Antituberculosos/uso terapéutico , Claritromicina/administración & dosificación , Claritromicina/efectos adversos , Esquema de Medicación , Farmacorresistencia Microbiana , Quimioterapia Combinada , Inhibidores Enzimáticos/uso terapéutico , Etambutol/uso terapéutico , Femenino , Fluoroquinolonas , Humanos , Kanamicina/uso terapéutico , Masculino , Persona de Mediana Edad , Complejo Mycobacterium avium/efectos de los fármacos , Rifampin/uso terapéutico , Análisis de Supervivencia , Resultado del Tratamiento
3.
Kekkaku ; 73(10): 591-7, 1998 Oct.
Artículo en Japonés | MEDLINE | ID: mdl-9844347

RESUMEN

A 52-year-old woman with visual loss of her left eye consulted a ophthalmology clinic. She was conducted left vitrectomy and administered corticosteroid under the diagnosis of uveitis of unknown cause. But her visual acuity was not improved. Although re-surgery was planned, pus retention was found in her left eye. After her left eye was resected, fever and general malaise appeared suddenly. Her chest X-ray film revealed diffuse micronodular opacities. Acid-fast bacilli were detected from her sputum and identified to be Mycobacterium tuberculosis. She was diagnosed miliary tuberculosis, and then antituberculous chemotherapy consisting of 4 drugs was started. Granulomatous inflammation destructing retina and numerous acid-fact bacilli were found in histologic examination of the resected eye. This case was thought to be miliary tuberculosis disseminated from intraocular tuberculosis. After 2 months of therapy, neurologic symptoms which might be caused by brain tuberucloma appeared and deteriorated rapidly. But by adding corticosteroid to antituberculous therapy, symptoms were diminished gradually.


Asunto(s)
Tuberculoma Intracraneal/etiología , Tuberculosis Miliar/etiología , Tuberculosis Ocular/complicaciones , Antiinflamatorios/administración & dosificación , Antituberculosos/administración & dosificación , Betametasona/administración & dosificación , Quimioterapia Combinada , Femenino , Humanos , Persona de Mediana Edad , Tuberculoma Intracraneal/tratamiento farmacológico , Tuberculosis Miliar/tratamiento farmacológico , Tuberculosis Ocular/tratamiento farmacológico
4.
Int J Tuberc Lung Dis ; 2(11): 935-40, 1998 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9848616

RESUMEN

SETTING: A commercially available polymerase chain reaction (PCR) test (Roche AmplicorTM Mycobacterium avium and M. intracellulare assay-MAC-PCR) designed to detect M. avium complex (MAC) in bronchial washing was evaluated. DESIGN: A total of 141 specimens from 127 patients with various pulmonary conditions were examined. Results were compared with acid-fast smears, cultures with Ogawa egg medium, as is still commonly used in Japan, and final diagnoses. RESULTS AND CONCLUSIONS: A total of 14 bronchial washing specimens yielded MAC. Six smear- and culture-positive specimens were all MAC-PCR positive. In eight smear-negative and culture-positive specimens, six were MAC-PCR positive. The overall sensitivity versus culture was 85.7% (12/14). However, sensitivity might be over-estimated, as there is a lower recovery rate of MAC with egg-based medium compared with liquid media. In 127 patients, 15 were identified as having pulmonary MAC disease, of whom 13 had positive MAC-PCR in bronchial washing. In the remaining 112 patients, MAC-PCR was negative, which suggests that positive MAC-PCR was not a contaminated result. However, in terms of sensitivity and speed, we were unable to show any additional clinical benefit for using MAC-PCR as opposed to liquid media, in which MAC can frequently be detected in 7 to 14 days.


Asunto(s)
Líquido del Lavado Bronquioalveolar/microbiología , Complejo Mycobacterium avium/aislamiento & purificación , Reacción en Cadena de la Polimerasa/métodos , Adulto , Anciano , Técnicas Bacteriológicas , Estudios de Evaluación como Asunto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Complejo Mycobacterium avium/genética , Infección por Mycobacterium avium-intracellulare/microbiología , Sensibilidad y Especificidad
5.
Eur Respir J ; 12(3): 607-11, 1998 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9762788

RESUMEN

Several substances including proteases and restrictocin have been suggested as candidates for virulence determinants in invasive pulmonary aspergillosis. However, the roles of such substances are not well understood. This study compared the in vitro suppressive effects of Aspergillus fumigatus culture filtrates (ACFs), on the functions of human polymorphonuclear leukocytes (PMNLs), the principal cells in the host defence against aspergillus hyphae, from a clinically isolated wild-type and isogenic mutant strains which lack production of elastolytic alkaline protease (Alp) and/or restrictocin. ACFs were obtained by culturing conidia of each strain in Medium- 199 at 37 degrees C for 5 days. ACFs of the wild-type significantly (p<0.01) suppressed chemotaxis, superoxide anion (O2-) release and PMNL-mediated hyphal damage, compared with the control (Medium-199). ACFs of the mutant strains that lack Alp or restrictocin significantly (p<0.01) suppressed chemotaxis and O2(-)-release, but did not suppress hyphal damage, compared with the control. The wild-type significantly (p<0.01) suppressed chemotaxis of PMNLs compared with the mutant strains lacking Alp or restrictocin, whereas there were no significant differences in suppression of O2(-)-release and hyphal damage by PMNLs. ACF of a mutant strain that lacks both Alp and restrictocin had much less activity, but significantly (p<0.01) suppressed chemotaxis of PMNLs compared with the control. In conclusion, alkaline protease and restrictocin may play roles in the suppressive effect of Aspergillus fumigatus culture filtrates on the functions of human polymorphonuclear leukocytes. Other antiphagocytic substances produced by Aspergillus fumigatus remain to be identified.


Asunto(s)
Alérgenos , Aspergillus fumigatus/enzimología , Quimiotaxis/fisiología , Leucocitos Mononucleares/fisiología , Serina Endopeptidasas/metabolismo , Antígenos de Plantas , Aspergilosis Broncopulmonar Alérgica/sangre , Aspergillus fumigatus/clasificación , Aspergillus fumigatus/genética , Proteínas Fúngicas/metabolismo , Humanos , Técnicas In Vitro , Inhibidores de la Síntesis de la Proteína/metabolismo , Ribonucleasas/metabolismo , Especificidad de la Especie , Superóxidos/metabolismo
6.
Eur Respir J ; 11(5): 1064-9, 1998 May.
Artículo en Inglés | MEDLINE | ID: mdl-9648956

RESUMEN

Eosinophils are considered to play a central pathogenetic role in asthma. We previously reported that sputum eosinophilia was observed in patients with cough variant asthma (CVA), as well as in "classic" asthma with wheezing. This study was undertaken to further investigate the involvement of eosinophils in CVA. The serum eosinophil cationic protein (ECP) level, the percentage of eosinophils in bronchoalveolar lavage (BAL) fluid, and the number of eosinophils in bronchial biopsy specimen were examined in 14 patients with CVA, 21 with classic asthma, and in seven healthy controls. For the two asthmatic groups, the clinical severity was classified with scores of 1-3. Pulmonary function and bronchial responsiveness were not significantly different between the patients with classic asthma and those with CVA. BAL, tissue eosinophil and serum ECP were all significantly increased in both classic asthma and CVA when compared with the controls but were not different between classic asthma and CVA. In both groups of asthmatics, the clinical severity significantly correlated with serum ECP and tissue eosinophils. In conclusion, eosinophilic inflammation is involved in cough variant asthma as well as in classic asthma. Anti-inflammatory treatment may be essential in patients with CVA, as in those with classic asthma.


Asunto(s)
Asma/complicaciones , Asma/patología , Bronquitis/patología , Tos/etiología , Eosinófilos/patología , Ribonucleasas , Adulto , Anciano , Asma/fisiopatología , Biopsia , Células Sanguíneas/patología , Proteínas Sanguíneas/análisis , Bronquios/patología , Bronquios/fisiopatología , Líquido del Lavado Bronquioalveolar/citología , Proteínas en los Gránulos del Eosinófilo , Femenino , Humanos , Mediadores de Inflamación/sangre , Masculino , Persona de Mediana Edad , Pruebas de Función Respiratoria
7.
Kansenshogaku Zasshi ; 72(4): 352-7, 1998 Apr.
Artículo en Japonés | MEDLINE | ID: mdl-9621563

RESUMEN

During the 7 years from 1990, thirty-two patients (20 in male and 12 in female, mean age; 53 years old) were diagnosed as having pulmonary cryptococcosis. To clarify the essential points for early diagnosis of pulmonary cryptococcosis, we reviewed the clinical records and chest images. Three patients had a past history of pulmonary tuberculosis and eleven patients had underlying disorders such as malignancy, chronic pulmonary diseases and so on, but no HIV infection, which would affect this disease. Eighteen patients did not have any past history nor complications. The symptoms such as cough, sputum, chest pain and fever were generally of low-grade, 14 patients had no symptom at diagnosis. Except of some patients with severe infections and severe underlying disorders, laboratory findings such as inflamatory and nutritious markers were almost within near the normal range. On plain chest X-ray films the distribution of lesions was almost in proprtion to the volume of the lobes. The multifocal nudular and/or infitrative shadows wer observed in about 2/3 cases and single lesion in about 1/3. The width of lesions were minimal except of one case with interstitial pneumonia and two cases with multifocal segmental pneumonia. The cavity lesions were observed in 7 cases and hilar lymphadenopathy in 3 cases. On CT images, the lesions were almost located in the outer zone, the lesions which were adjacent to the pleura were observed in 15 cases. Cavitary lesions were almost smooth in edge and ubiquitous, the walls were also thick. The peripheral air-bronchogram in the nodular/infitrative shadows were observed in three cases. Pulmonary cryptococcosis is air-borne and almost a chronic infection except in AIDS patients, so careful planning for examination is essential with considerations of the characteristics of clinical and imaging features of this infection.


Asunto(s)
Criptococosis/diagnóstico , Enfermedades Pulmonares Fúngicas/diagnóstico , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad
8.
Int J Tuberc Lung Dis ; 2(3): 258-60, 1998 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9526201

RESUMEN

We present the first reported case of Mycobacterium szulgai pulmonary disease that needed surgical resection due to unsuccessful antimycobacterial chemotherapy. The patient was a non-immunocompromised 48-year-old male who presented with hemoptysis and whose sputum cultures repeatedly yielded M. szulgai. Antimycobacterial chemotherapy with isoniazid (INH) and rifampin (RMP)/ethambutol (EMB) for three years had been unsuccessful, and subsequent chemotherapy with RMP, EMB, ethionamide and kanamycin had to be discontinued due to liver dysfunction. Surgical resection was finally performed, and resulted in a favorable outcome. Although M. szulgai pulmonary disease is usually well controlled by antimycobacterial chemotherapy alone, surgical treatment may be necessary in some cases.


Asunto(s)
Infecciones por Mycobacterium no Tuberculosas/cirugía , Tuberculosis Pulmonar/cirugía , Antituberculosos/administración & dosificación , Antituberculosos/efectos adversos , Quimioterapia Combinada , Etambutol/administración & dosificación , Etambutol/efectos adversos , Etionamida/administración & dosificación , Etionamida/efectos adversos , Humanos , Isoniazida/administración & dosificación , Kanamicina/administración & dosificación , Kanamicina/efectos adversos , Masculino , Persona de Mediana Edad , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico , Rifampin/administración & dosificación , Resultado del Tratamiento , Tuberculosis Pulmonar/tratamiento farmacológico
9.
Clin Exp Allergy ; 28(2): 233-40, 1998 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9515598

RESUMEN

BACKGROUND: The serum level of eosinophil cationic protein (ECP) has been used as a clinical marker in asthma, on the assumption that it reflects ongoing eosinophilic inflammation of the airways. However, only a few studies have investigated this issue, using bronchial secretions but not tissue specimens. OBJECTIVE: To evaluate cross-sectionally the correlation between serum ECP level or blood eosinophil count, and the degree of eosinophilia in bronchoalveolar lavage fluid (BALF) and bronchial biopsy tissue, and disease activity, in asthmatic patients. METHODS: Thirty-three adults with symptomatic asthma and six healthy controls were studied. The blood eosinophil count, ECP levels in serum and BALF, percentage of eosinophils in BALF, number of eosinophils in bronchial tissue, pulmonary function, and methacholine bronchial responsiveness of these subjects were clarified. An asthma severity score and inhaled beta2-agonist requirement (puffs/day) were also assessed for the asthmatic patients. RESULTS: The asthmatic patients, compared with the controls, had more obstructive (as tested by %FEV1, FEV1/FVC, and FEF25-75%) and more responsive airways, and showed a significant increase in the number of eosinophils in the blood, BALF, and tissue, and in the serum ECP levels. The ECP levels in BALF were below the detection limit for most of the subjects in both groups examined. In the asthmatic patients, serum ECP level demonstrated correlations with the number or percentage of eosinophils in BALF and tissue, whereas the blood eosinophil count correlated only with the percentage of eosinophils in BALF. Serum ECP level correlated with all indices of disease activity examined; %FEV1, FEV1/FVC, FEF25-75% bronchial responsiveness, severity score and beta2-agonist usage, whereas the blood eosinophil count correlated only with %FEV1 and bronchial responsiveness. CONCLUSION: The data suggest that serum ECP level reflects the intensity of eosinophilic airway inflammation, as well as the disease activity, and may be useful as an inflammatory marker in asthma.


Asunto(s)
Asma/inmunología , Proteínas Sanguíneas/análisis , Bronquitis/inmunología , Eosinofilia/inmunología , Mediadores de Inflamación/análisis , Ribonucleasas , Adulto , Asma/sangre , Asma/diagnóstico , Bronquios/citología , Pruebas de Provocación Bronquial , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Proteínas en los Gránulos del Eosinófilo , Eosinófilos/citología , Eosinófilos/metabolismo , Femenino , Flujo Espiratorio Forzado , Volumen Espiratorio Forzado , Humanos , Recuento de Leucocitos , Masculino , Persona de Mediana Edad
10.
Infect Immun ; 65(11): 4405-10, 1997 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9353012

RESUMEN

Macrophage-derived interleukin-12 (IL-12) is essential for the activation of a protective immune response against intracellular pathogens. In this study, we examined the regulation of IL-12 mRNA expression by monocyte-derived macrophages (MDM) in response to Mycobacterium bovis BCG stimulation. A reverse transcription-PCR assay detected p40 mRNA of IL-12 at 3 h and showed a peak at 6 to 12 h with a subsequent decline. Semiquantitation of mRNA levels by competitive PCR revealed that pretreatment with gamma interferon (IFN-gamma) amplified the expression approximately 100-fold, while pretreatment with tumor necrosis factor alpha (TNF-alpha) or granulocyte-macrophage colony-stimulating factor augmented this expression about 10-fold. In contrast, pretreatment with IL-10 and IL-4 inhibited IL-12 mRNA expression. These results were further confirmed by measuring the p70 bioactive protein level in each conditioned medium by an enzyme-linked immunosorbent assay. Since IL-12 mRNA expression was weak without cytokine pretreatment and IFN-gamma strongly augmented production, we speculated that IFN-gamma might have a role in BCG stimulation of IL-12 mRNA expression. Unexpectedly, the addition of three different kinds of anti-IFN-gamma antibodies and anti-IFN-gamma receptor antibody and the coaddition of anti-TNF-alpha antibody with anti-IFN-gamma receptor antibody all failed to inhibit IL-12 mRNA expression. However, the MiniMACS method used to remove NK cells from a mononuclear cell suspension inhibited the expression of p40 mRNA but not the expression of mRNA of TNF-alpha or IL-1beta. We concluded that the coexistence of NK cells was essential for the induction of IL-12 in MDM stimulated with BCG rather than through the secretion of IFN-gamma.


Asunto(s)
Citocinas/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Interleucina-12/genética , Células Asesinas Naturales/fisiología , Macrófagos/metabolismo , Mycobacterium bovis/fisiología , Humanos , ARN Mensajero/análisis
11.
Am J Respir Crit Care Med ; 155(6): 2041-6, 1997 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9196113

RESUMEN

Mycobacterium avium complex (MAC) pulmonary disease with nodules and bronchiectasis is increasing. But the usefulness of computed tomography (CT) and bronchoscopy for diagnosis and the significance of MAC isolation from respiratory secretions are still unclear. For a 4-yr period, we prospectively examined the role of bronchoscopy with bronchial washing and transbronchial lung biopsy in 26 patients who had clusters of small nodules in the periphery of the lung associated with ectatic changes of the draining bronchi on the CT scan. None of them was infected with human immunodeficiency virus. Thirteen of the 26 patients (50%) had cultures positive for MAC, six in the sputum and 13 in the bronchial washing. Epithelioid granuloma was demonstrated in eight of 13 patients with culture-positive MAC and in two of 13 patients in whom MAC was culture-negative. Rapidly growing mycobacteria were cultured in the two patients. Seven of the eight biopsy-positive patients received treatment and responded by sputum conversion and/or radiographic improvement. We found that the CT finding was a useful clue to suspect MAC pulmonary disease and that the bronchial washing was more sensitive than the routine expectorated sputum for MAC isolation. Demonstration of granuloma in more than half of the MAC-positive patients would suggest that MAC may have invaded the lung tissue rather than colonized in the airways.


Asunto(s)
Broncoscopía , Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/microbiología , Infección por Mycobacterium avium-intracellulare/complicaciones , Infección por Mycobacterium avium-intracellulare/diagnóstico , Tomografía Computarizada por Rayos X , Adulto , Anciano , Biopsia , Broncoscopía/efectos adversos , Femenino , Humanos , Pulmón/diagnóstico por imagen , Pulmón/patología , Enfermedades Pulmonares/terapia , Masculino , Persona de Mediana Edad , Complejo Mycobacterium avium/aislamiento & purificación , Infección por Mycobacterium avium-intracellulare/microbiología , Estudios Prospectivos , Esputo/microbiología , Irrigación Terapéutica , Resultado del Tratamiento
12.
Kekkaku ; 72(4): 187-92, 1997 Apr.
Artículo en Japonés | MEDLINE | ID: mdl-9145648

RESUMEN

Fifty six clinical isolates of Mycobacterium tuberculosis were tested for drug susceptibility in Mycobacteria Growth Indicator Tube (MGIT) containing 0.1 microgram/ml of INH, 1.0 microgram/ml of RFP, 3.5 micrograms/ml of EB and 0.8 microgram/ml of SM. These results were compared with those obtained by testing the same M.tuberculosis isolates by the absolute concentration method using 1% Ogawa egg slant containing 0.1 microgram/ml of INH, 10 micrograms/ml of REP, 2.5 micrograms/ml of EB and 20 micrograms/ml of SM. Fifty six isolates consisted of 18 pansensitive strains, 27 multidrug resistant strains and 11 single drug resistant strains. The results of individual drugs showed excellent agreement between the MGIT and the Ogawa methods, and overall agreement rate of the two methods were 96.4%. The results were just the same for all drugs in 48 out of 56 strains studied. The drug resistance could be observed much earlier by the MGIT method (mean 5.9 days) than by the Ogawa method (more than 21 days). In conclusion, the MGIT system could be a promising new drug susceptibility test which might become available in Japan replacing the Ogawa method.


Asunto(s)
Pruebas de Sensibilidad Microbiana/instrumentación , Mycobacterium tuberculosis/efectos de los fármacos , Antituberculosos/farmacología , Estudios de Evaluación como Asunto
14.
Kekkaku ; 72(1): 1-7, 1997 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-9038009

RESUMEN

A nationwide study was conducted to investigate the efficacy of Clarithromycin (CAM) on pulmonary atypical mycobacteriosis caused by the Mycobacterium avium-Mycobacterium intracellulare complex, including intractable cases. Out of total 97 patients examined, the analysis for bacteriological efficacy was possible in 69 cases. The negative conversion of bacilli was observed in 18 cases (26.1%), and 5 out of 12 cases in which the follow-up was conducted turned out continued negative status. The efficacy of CAM was relatively high in the following cases: the duration of the disease was less than 6 months the extent of pulmonary lesions on chest roentogenograms was limited or moderate; and antituberculous agents which were previously unused were applied in combination with CAM. Also, the efficacy was high in cases where the dose of CAM was 600 mg/day or higher. Major side effect was mill to moderate digestive symptoms. In conclusion, at daily dose of 600 mg or higher, CAM was effective in the elimination or reduction of M avium M. intracellulare complex that caused atypical mycobacteriosis, without developing serious side effect. Treatment with this drug should be attempted in intractable cases.


Asunto(s)
Antibacterianos/uso terapéutico , Antituberculosos/uso terapéutico , Claritromicina/uso terapéutico , Infección por Mycobacterium avium-intracellulare/tratamiento farmacológico , Tuberculosis Pulmonar/tratamiento farmacológico , Femenino , Humanos , Masculino , Resultado del Tratamiento
15.
Kekkaku ; 72(1): 15-20, 1997 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-9038011

RESUMEN

We reported 2 cases of Mycobacterium avium complex lung disease occurred in middle-aged women without underlying disorders, which we could observe for more than 30 years. One case was a 42-year-old woman started with bloody sputum, and the other was a 43-year-old woman with cough and sputum. In both cases, chest X ray films were normal on their first visit. More than 15 years after their first visit, Mycobacterium avium complex was isolated from their sputum or bronchial washing. During the observation, a cluster of small nodules in the periphery of the lung and bronchiectasis appeared and deteriorated, and excretion of the bacilli increased gradually. Their past history and family history were normal. Since lung disease caused by Mycobacterium avium complex progresses very slowly, long-time observation would be necessary to consider its pathogenesis.


Asunto(s)
Infección por Mycobacterium avium-intracellulare/diagnóstico por imagen , Tuberculosis Pulmonar/diagnóstico por imagen , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Persona de Mediana Edad , Factores de Tiempo , Tomografía Computarizada por Rayos X
17.
Int J Tuberc Lung Dis ; 1(5): 460-7, 1997 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9441102

RESUMEN

SETTING: The activity of KRM 1648 (KRM), a new benzoxazinorifamycin, and rifabutin (RBT), alone or in combination with clarithromycin (CLA), was evaluated against Mycobacterium avium complex (MAC) that multiplied in human alveolar macrophages (AM). DESIGN: AM were recovered by bronchoalveolar lavage, incubated in RPMI 1640 medium with 10% human AB serum, infected with four strains of MAC (of non-acquired immune deficiency syndrome [AIDS] origin), and then treated with each drug alone or in combination. After incubation for 7 days, colony forming units in each well were counted on 7H10 agar. RESULTS: Although concentrations between 0.2 microgram/ml and 20 micrograms/ml of both rifamycins showed clear dose-dependent activities against all MAC strains tested, only 20 micrograms/ml of each drug had modest bactericidal effect. In combination with 2.0 micrograms/ml of CLA, however, 0.2 microgram/ml of both drugs caused a bactericidal response against two of the four MAC strains examined. CONCLUSION: According to this human alveolar macrophage model of MAC infection, KRM and RBT in combination with CLA was found to be a promising candidate against human pulmonary MAC infection, and deserves clinical evaluation.


Asunto(s)
Antibacterianos/farmacología , Antibióticos Antituberculosos/farmacología , Claritromicina/farmacología , Macrófagos Alveolares/efectos de los fármacos , Complejo Mycobacterium avium/efectos de los fármacos , Rifabutina/farmacología , Rifamicinas/farmacología , Adulto , Lavado Broncoalveolar , Células Cultivadas , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Femenino , Humanos , L-Lactato Deshidrogenasa/efectos de los fármacos , L-Lactato Deshidrogenasa/metabolismo , Macrófagos Alveolares/metabolismo , Macrófagos Alveolares/microbiología , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Complejo Mycobacterium avium/crecimiento & desarrollo , Valores de Referencia , Fumar
18.
Intern Med ; 35(11): 839-40, 1996 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-8968791
19.
J Allergy Clin Immunol ; 97(6): 1308-19, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8648028

RESUMEN

OBJECTIVE: The study was designed to establish an animal model of toluene diisocyanate (TDI)-induced late respiratory response and to investigate airway inflammatory cell dynamics in this model. METHODS: Guinea pigs were exposed to 2, 4-TDI dissolved in ethyl acetate by nasal application according to three schedules. Schedule 1 consisted of sensitization and multiple challenge (n = 58): 10% TDI was applied once daily for 7 days (sensitization) followed by challenges with 5% TDI once weekly for 4 weeks. Schedule 2 consisted of sensitization only (n = 5): 10% TDI was applied once daily for 7 days. Schedule 3 consisted of single challenge only (n = 12): 5% TDI was applied only once. As controls, ethyl acetate was applied according to the three schedules described above. Each animal was premedicated with metyrapone before each challenge. Bronchoalveolar lavage and histologic examination were performed at various times after the last challenge. RESULTS: Schedule 1 induced immediate and late respiratory responses at a prevalence of 63% and 56%, respectively. Schedules 2 and 3 induced an immediate response in some animals but no late response. Neither immediate nor late response was observed in control animals. All of the subgroups of schedule 1 that developed late responses (examined at 2, 3, 6, 24 and 168 hours) showed a significant increase of eosinophils in bronchoalveolar lavage fluid and tissue compared with the corresponding control of each (examined at the same time points). Two of the subgroups with late responses (examined at 3 and 6 hours) were compared with their corresponding subgroups, which were given the same treatment, failed to develop late response, and were examined at the same time points; they again proved to have a significant increase of eosinophils in both samples. Subgroups of schedule 1 without late response (30 minutes, 3 and 6 hours), schedule 2 (6 hours), or schedule 3 (2 and 6 hours) did not show significant changes in lavage or tissue cell composition, except for the schedule 1 subgroup examined at 6 hours, which showed a significant increase of eosinophils only in the tissue compared with its control. CONCLUSIONS: Sensitization and multiple challenge with TDI induced immediate and/or late respiratory responses at a high prevalence in guinea pigs. Eosinophilic but not neutrophilic inflammation was involved in the late response.


Asunto(s)
Asma/fisiopatología , 2,4-Diisocianato de Tolueno/inmunología , Animales , Asma/patología , Bronquios/patología , Líquido del Lavado Bronquioalveolar/citología , Inhibidores Enzimáticos/farmacología , Eosinófilos/inmunología , Cobayas , Hidrocortisona/biosíntesis , Recuento de Leucocitos , Recuento de Linfocitos , Macrófagos , Masculino , Metirapona/farmacología , Neutrófilos , Respiración , Factores de Tiempo
20.
J Clin Microbiol ; 34(6): 1433-9, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8735094

RESUMEN

Aspergillus spp. occasionally cause invasive pulmonary aspergillosis following noninvasive infection in patients with underlying bronchopulmonary disorders regardless of their systemic immunological conditions. We developed a murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection. BALB/c mice were inoculated intratracheally with agarose beads containing Aspergillus fumigatus conidia. Two weeks after inoculation, half of the mice were immunosuppressed with cortisone acetate. During a 4-week observation period, the survival rate of infected immunosuppressed mice was significantly lower (P < 0.01) than that of infected nonimmunosuppressed mice. The number of CFU in the lungs gradually decreased in the nonimmunosuppressed mice, whereas a time-related significant increase (P < 0.05) of CFU was demonstrated in the immunosuppressed mice. In the lungs of the nonimmunosuppressed mice, there was marked accumulation of neutrophils, lymphocytes, and macrophages (in this order) around the agarose beads in the bronchi. Aspergillus hyphae were surrounded by the inflammatory cells and did not invade the lung parenchyma. In contrast, in the immunosuppressed mice, Aspergillus hyphae proliferated markedly and invaded the lung parenchyma after immunosuppression. In this model, the two-dimensional extents of the lesions were also evaluated with an image-processing system. Time-related increase of the area of peribronchial necrotic lesions was significant (P < 0.05) after immunosuppression. This model should therefore be useful for investigating the pathophysiology of noninvasive Aspergillus infection and invasive pulmonary aspergillosis and also for clarifying the mechanism of conversion to the invasive disease from the noninvasive stage.


Asunto(s)
Aspergilosis/etiología , Aspergillus fumigatus , Enfermedades Pulmonares Fúngicas/etiología , Animales , Aspergilosis/microbiología , Aspergilosis/patología , Aspergillus fumigatus/aislamiento & purificación , Aspergillus fumigatus/patogenicidad , Recuento de Células , Cortisona/análogos & derivados , Cortisona/farmacología , Modelos Animales de Enfermedad , Femenino , Tolerancia Inmunológica/efectos de los fármacos , Huésped Inmunocomprometido , Enfermedades Pulmonares Fúngicas/microbiología , Enfermedades Pulmonares Fúngicas/patología , Ratones , Ratones Endogámicos BALB C , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...